美国非酒精性脂肪性肝病患者他汀使用趋势
该研究基于2005至2018年美国国家健康与营养调查(NHANES)连续数据,纳入14 113名成人,其中34.6%患有非酒精性脂肪性肝病(NAFLD)。NAFLD患者中他汀用于一级预防的比例从2005年的18.1%升至2018年的25.0%(P=0.03),但符合指南指征的使用率仍低(2005-2012年为54.5%,2013-2018年为48.6%)。已知肝病诊断在早期是使用他汀的负面预测因素,但近期不再如此;使用率未随肝病严重程度增加而降低。
要点
- NAFLD患者他汀一级预防使用率从18.1%升至25.0%,但指南符合率仍低。
- 已知肝病诊断在早期与未使用他汀相关,近期该关联消失。
- 他汀使用未随肝病严重程度增加而减少。
核心结论
- NAFLD患者他汀一级预防使用率随时间增加,但符合指南的使用率仍低。
- 已知肝病诊断在早期与未使用他汀相关,近期不再相关,提示对肝病影响他汀使用的看法在改变。
研究设计与样本
- 基于2005至2018年连续NHANES数据,纳入14 113名成人,其中34.6%患有NAFLD,5.4%报告有肝病诊断。
- 评估他汀使用趋势及一级预防中他汀未使用的预测因素,并分析已知肝病诊断和疾病严重程度的作用。
主要发现
- NAFLD患者他汀一级预防使用率从2005年的18.1%升至2018年的25.0%(P=0.03)。
- 符合指南指征的他汀一级预防使用率在2005-2012年为54.5%,2013-2018年为48.6%。
- 已知NAFLD诊断在早期是使用他汀的负面预测因素,但近期不再如此。
- 他汀使用率未随肝病严重程度增加而降低。
临床怎么用
- 临床医生应关注NAFLD患者心血管疾病风险,按指南指征处方他汀进行一级预防。
- 不应因已知肝病诊断而避免使用他汀,且肝病严重程度不构成减少他汀使用的理由。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has high morbidity and mortality related to cardiovascular disease (CVD), but statins have been historically underutilised in these patients due to concern for hepatotoxicity. AIMS: To characterise trends in statin use among individuals with NAFLD and to determine predictors of statin utilisation in this population. METHODS: Individuals with NAFLD were identified from 2005 to 2018 continuous National Health and Nutrition Examination Survey. Trends in statin use over time were assessed, and predictors of statin under-utilisation for primary prevention were identified. The roles of a known diagnosis of liver disease and disease severity were examined. RESULTS: We included 14 113 individuals; 34.6% had NAFLD, of whom 5.4% reported a liver disease diagnosis. There was a significant increase in statin use for primary prevention between 2005 and 2018 (18.1%-25.0%; P = 0.03), but guideline-indicated use for this purpose was low (54.5% between 2005 and 2012; 48.6% between 2013 and 2018). A known NAFLD diagnosis was a negative predictor of statin use during the earlier time period but not more recently. Utilisation did not decrease with increasing liver disease severity. CONCLUSIONS: In a nationally representative population with NAFLD, statin use for primary prevention has increased over time, but guideline-concordant use remains low. A known liver disease diagnosis was associated with lack of statin use in the earlier time period but not more recently, suggesting a changing perspective of underlying liver disease impacting statin utilisation. Further work to improve guideline-indicated statin use in this high-risk population is needed.
引用
- Henson JB, Patel YA, Muir AJ, et al. Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021. PMID: 34653272. doi:10.1111/apt.16646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。